Eli Lilly Canada Inc. v. Novopharm Limited, 2011 FC 1288 (Olanzapine*)

Justice O'Reilly - 2011-11-10

Read full decision. Automatically generated summary:

The plaintiffs [collectively "Lilly"] sued Novopharm for infringement of a patent for a medicine called olanzapine, whose brand name is Zyprexa. Psychiatrists prescribe olanzapine primarily for the treatment of schizophrenia. Novopharm markets a generic version of olanzapine, called novo-olanzapine. Olanzapine is the subject of a Canadian patent (No 2,041,113) [the '113 patent]. Lilly applied for the '113 patent in 1991 and was granted it in 1998.

Decision relates to:


Canadian Intellectual Property